Compatible with Any Real-Time PCR Platform, New Reagents Offer Superior Results Combined with Informatics Tools to Simplify Multiplexing
SAN DIEGO--(BUSINESS WIRE)--Jul. 23, 2012-- Illumina, Inc. (NASDAQ:ILMN) today launched its real-time PCR reagent portfolio, including a novel, probe-based chemistry for gene expression analysis called NūPCR™. In addition to the NuPCR Reagents, Illumina announced qPCR DNA Binding Dye (DBD) Assays for Gene Expression Analysis and qPCR High Resolution Melting (HRM) Assays for genotyping studies, providing researchers with a trio of high-quality, budget-friendly options in the qPCR reagent market.
NuPCR is a novel probe-based qPCR technology that is designed to show improved specificity and sensitivity to complex gene targets, as compared to existing qPCR technologies on the market today. Leveraging the power of DesignStudio™, a personalized, web-based design tool available to Illumina customers, NuPCR allows researchers the ability to quickly build custom multiplexed assays. This unique, easy-to-use software delivers bioinformatically optimized assays, ensuring high PCR efficiencies and assays that work the first time without tedious trial and error optimization. In addition, NuPCR, DBD, and HRM assays are compatible with any real-time PCR instrument platform, offering researchers a wider range of reagent choices to implement on their existing instrumentation.
“Illumina is excited to offer these high-quality reagents at a disruptive price point. Now customers can perform more experiments with their current resources and on any platform,” said Mark Lewis, Senior Vice President and General Manager, Molecular Biology and PCR Business, Illumina. “By combining these reagents with our current real-time PCR instrument, Eco™, Illumina is also now able to provide customers with a complete real-time PCR solution.”
According to Randal J. Kaufman, Ph.D., Director of Degenerative Disease Research at Sanford-Burnham Medical Research Institute, “Real-time PCR methodology is integral to our research and thus, we were very excited to learn about Illumina’s NuPCR technology. DesignStudio makes it easy to design and order probes, especially for our multiplex reactions.” Dr. Kaufman, an early access customer, added, “We anticipate the product’s quality, lower cost and simplified multiplexing will yield substantial savings over other probe-based technologies.”
Illumina NuPCR reagents, DBD assays, and HRM assays are available through Illumina’s extensive international distributor network. Availability of NuPCR in the United States will be announced in the near future.
For more information about the new reagents and the complete Illumina real-time PCR solution, visit www.illumina.com/NuPCR.
About Illumina
Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.
Forward-Looking Statements
This release may contain forward looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those in any forward-looking statements are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.
Source: Illumina, Inc.
Illumina, Inc.
Investors:
Kevin Williams, MD
Investor Relations
858-332-4989
kwilliams@illumina.com
or
Media:
Jennifer Temple
Public Relations
858-882-6822
pr@illumina.com
